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We have recently suggested a novel mechanism, autoendocytosis, for the entry of certain microbes into their hosts, with a key
role played by the sphingomyelinase-catalyzed topical conversion of sphingomyelin to ceramide, the differences in the biophysical
properties of these two lipids providing the driving force. The only requirement for such microbes to utilize this mechanism is
that they should have a catalytically active SMase on their outer surface while the target cells should expose sphingomyelin in the
external leaflet of their plasmamembrane. In pursuit of possible microbial candidates, which could utilize this putative mechanism,
we conducted a sequence similarity search for SMase. Because of the intriguing cellular and biochemical characteristics of the poorly
understood entry of Chlamydia into its host cells these microbes were of particular interest. SMase activity was measured in vitro
from isolated C. pneumoniae elementary bodies (EB) and in the lysate from E. coli cells transfected with a plasmid expressing
CPn0300 protein having sequence similarity to SMase. Finally, pretreatment of host cells with exogenous SMase resulting in loss
plasma membrane sphingomyelin attenuated attachment of EB.
1. Introduction
Sphingomyelinase (SMase, sphingomyelin phosphodiester-
ase, E.C.3.1.4.12) is a hydrolytic enzyme, which cleaves
the phosphocholine moiety from sphingomyelin, yielding
ceramide. Interestingly, there is a wide range of bacteria,
viruses, and parasites, which need ceramide in one way or
another to enter nonphagocytic cells and to cause infection,
for example, Neisseria gonorrhoeae [1], Pseudomonas aerugi-
nosa [2], Staphylococcus aureus [3], Semliki Forest virus [4],
Sindbis virus [5], and Rhinovirus [6]. Likewise, Plasmodium
falciparum needs SMase for the infection of erythrocytes [7].
Themolecular levelmechanisms have remained elusive.Pseu-
domonas andNeisseria activate the SMase of the host cell but,
for example, the most virulent Mycobacteria [8], Clostridium
perfringens [9], Bacillus cereus [10], Listeria monocytogenes
[11], Helicobacter pylori [12], and Leptospira interrogans [13],
have endogenous SMase or sphingomyelinase-like protein.
We have previously demonstrated following a topical
microinjection of SMase a vectorial formation of ceramide
enriched vesicles in sphingomyelin containing giant lipo-
some model membranes [14]. More specifically, a release
of “endocytotic” vesicles into the giant liposome or vesicle
budding from its outer surface was seen following the action
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of this enzyme either on the outer or the inner leaflet of
the vesicle, respectively. To this end, exogenous SMase has
been shown to induce in ATP-depleted macrophages and
fibroblasts pinching off into the cytoplasm of approximately
400 nm diameter vesicles from the plasma membrane [15].
There is evidence that budding and fusion may happen
without assisting proteins such as clathrin [16]. The mecha-
nistic basis of the above morphological transition induced by
SMase can be readily rationalized in forms of the distinctly
different biophysical characteristics of sphingomyelin and
ceramide. In brief, while sphingomyelin is miscible in fluid
phosphatidylcholine bilayers, ceramide is laterally segregated
[17, 18]. Accordingly, in the course of action of SMase on
mixed sphingomyelin/phosphatidylcholine membranes the
generated ceramide becomes enriched into microdomains
[19]. In terms of physical chemistry this represents an
isothermal transition triggered by an enzymatic reaction,
causing a shift in the lipid phase diagram from the fluid
disordered phase (ld) into the two phase region, consisting of
ld and solid ordered (ls) phases, the latter being enriched of
ceramide [20].
The lateral segregation of ceramide is likely to result from
an efficient intermolecular hydrogen bonding between the
small and weakly hydrated ceramide headgroups [19–23];
their tight lateral packing becomes allowed after the loss of
steric repulsion on the headgroup level due to the cleavage by
SMase of the strongly hydrated phosphocholinemoiety. Tight
packing is further augmented by chain-chain van der Waals
interactions and attenuated trans→ gauche isomerization.
Ceramide is readily expected to facilitate the formation of
macroscopic invaginations in themembrane [14] by imposing
membrane negative spontaneous curvature, the latter ulti-
mately manifesting as the formation of the inverted hexag-
onal phase HII by this lipid [24, 25]. Because of the interfacial
area per molecule, for ceramide is significantly smaller than
for sphingomyelin [21], the asymmetric enzymatic formation
of ceramide in a bilayer either in the outer or inner leaflet also
causes an area difference between the two monolayers. These
features, the area difference between the adjacent monolayer
leaflets and the negative spontaneous curvature of ceramide
containing domains, togetherwith their high bending rigidity
provide the driving force for the observed vectorial formation
of vesicles in the membrane upon the action of SMase [14].
Product diffusion, domain formation, and vectorial budding
into the substrate vesicle interior were seen also when an
immobilized SMase was acting on sphingomyelin containing
giant liposome membranes [26]. The latter study confirms
that it is the molecular properties of the reaction product and
not the lipid-protein interaction per se that is providing the
driving force.
Prompted by the above consequences of the SMase
reaction we have suggested that microbes harboring this
enzyme on their outer surface and contacting the extracellu-
lar leaflet of the plasma membrane of their target cell would
induce the above phase change with segregation of ceramide
and pinching of the microbe containing “autoendocytotic”
vesicles into the cytoplasm of the host cell [14]. Accordingly,
it was of interest to search protein sequence databases for
possible identification of microbes, which could potentially
utilize this mechanism. Because of the characteristic features
of the entry of the genus Chlamydia into their host cells these
microbes were of particular interest. These microorganisms
have an intriguing and unique developmental growth cycle.
In brief, the latter begins when the infectious, metabolically
inactive, and relatively small (0.3 𝜇m in diameter) elementary
bodies (EB) attach to the host cell surface, there after
somehow stimulating their uptake into the host inside plasma
membrane derived vacuoles called inclusions [27, 28]. Several
host receptors and surface ligands of EB have been suggested
to be involved in their attachment and internalization [29–
33]. Yet, the detailed molecular mechanisms of the entry of
Chlamydia into its host cells have remained elusive. Following
their internalization the EB differentiate within a few hours
into larger (about one 𝜇m in diameter) and metabolically
active reticulate bodies (RB). Subsequent replication and the
infectious cycle are completed in 2-3 days, when the bacteria
have again differentiated to EB, which are released from
the host into the extracellular media [27]. The infectious C.
pneumoniae EB contain the genomic DNA with a coding
capacity of approximately 1000 genes and are resistant to
environmental stresses, allowing their survival outside of the
host cells.
We searched in silico the putative surface proteins of
C. pneumoniae [34] for potential SMase sequences. More
specifically, we aligned the sequences of the suggested outer
membrane proteins of C. pneumoniae with the sequences
of a neutral SMase reference group (Table 1). Interestingly,
Tr|Q9Z8N8|Q9Z8N (CPn0300, an omp85 analog) ofC. pneu-
moniae scored very well (73/100) in the T-coffee alignment,
bearing a high degree of overall structural similarity to
the human neutral SMase sp|O60906|NSMA.The alignment
of the latter and Tr|Q9Z8N8|Q9Z8N revealed strong sim-
ilarities in the proton binding and substrate recognition
areas of SMases. The sequence of Tr|Q9Z8N8|Q9Z8N fur-
ther includes a general phosphate binding domain (IMP
dehydrogenase/GMP reductase domain), similar to that in
alkaline SMases. These studies were complemented by the
demonstration of SMase activity in C. pneumoniae EB in
vitro. A pretreatment of the host cell plasma membrane by
an exogenously added SMase attenuated the entry and/or
growth of C. pneumoniae in these cells.
2. Materials and Methods
2.1. Materials. Bodipy-sphingomyelin (Bdp-SM), Bodipy-
ceramide (Bdp-cer), and Amplex Red kit were obtained from
Molecular Probes (Eugene,OR).Thepurity of the above lipids
was verified by thin-layer chromatography (TLC) on sili-
cic acid-coated plates (Merck, Darmstadt, Germany) devel-
oped with chloroform/methanol/water (65 : 25 : 4, by vol.).
The concentrations of Bdp-SM and Bdp-cer in chloroform
were determined spectrophotometrically using 77,000 cm−1
and 91,000 cm−1, respectively, for their molar extinction
coefficients. [35S]-cysteine/methionine was obtained from
AmershamBiosciences. Proanalysis grade solvents were from
Merck, SMase from Staphylococcus aureus from Sigma, and
other chemicals from standard sources.
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Table 1: SMase reference group.
sp|P69502|SMAL LOXGA SMase loxnecrogin EC 3.1.4.41 Loxosceles gaucho (spider)
sp|Q7Z1Y7|SMAD LOXAR SMase D precursor EC 3.1.4.41 Loxosceles arizonica (arizona brown spider)
sp|P83045|SMA1 LOXIN SMase P1 precursor EC 3.1.4.41 Loxosceles intermedia (spider)
sp|P17627|PHL LEPIN SMase C precursor EC 3.1.4.12 Leptospira interrogans
sp|P80924|PHLC STAIN SMase C EC 3.1.4.12 Staphylococcus intermedius
sp|P09978|PHLC STAAU Phospholipase C precursor EC 3.1.4.3 Staphylococcus aureus
sp|P09599|PHL1 BACCE SMase C precursor EC 3.1.4.12 Bacillus cereus
sp|O60906|NSMA HUMAN NSMase 1 EC 3.1.4.12 Homo sapiens
2.2. Sequence Comparisons and Alignments. Sequences of
putative outer surface proteins of C. pneumoniae [34] were
aligned with those in our SMase reference group (Table 1).
The latter was randomly selected from all known SMase
sequences, with a high degree of overall diversity regarding
subfamilies and species. The outer membrane proteins of C.
pneumoniae that scored best with this reference group were
further aligned pairwise with the SMase of greatest resem-
blance in the reference group. Subsequently, the subfamily of
the aligned SMase was aligned against the protein candidate.
Special attention was issued to the conserved functionally
important sequences. T-coffee (version 2.88) was chosen for
this investigation because it has been demonstrated to be
more accurate than ClustalW for sequences with less than
30% identity [35]. This issue was of major concern as in
spite of possessing the same catalytic activity the sequence
similarity of SMases is weak, including their active sites (see
Section 4). Pfam (protein domain family database) motifs
[36] in CPn0300 were searched by the algorithm available in
Expasy (http://myhits.isb-sib.ch/) for the PROSITE database.
2.3. Preparation of C. pneumoniae EB. HL cells were grown
in Dulbecco modified Eagle’s medium (DMEM, Sigma)
containing 10% fetal calf serum and 20 𝜇g/mL gentamycin,
maintained at 37∘C under 5% CO
2
. C. pneumoniae isolate
Kajaani 6 (K6 [37], originally obtained from Prof. Saikku,
University of Oulu, Finland) was propagated in HL cells and
purified. In brief, infected cells were harvested and ultrasoni-
cally disrupted after the cell debris was removed and the bac-
teria purified by centrifugation in a meglumine diatrizoate
gradient [38]. Aliquots of the purified microbe were stored
at −70∘C in 0.25M sucrose, 10mM sodium phosphate, 4mM
potassium phosphate, and 5mM L-glutamic acid, pH 7.5
(SPG), until used. For host cell attachment assay, the bacteria
were metabolically labeled with [35S]-cysteine/methionine
[39]. The infective titers of the preparations were determined
in HL cell cultures and expressed as inclusion forming units
per mL (IFU/mL). When indicated the C. pneumoniae EB
stocks were inactivatedwithUV-light (2x of 0.120 joules/cm2;
Crosslinker CL-508, Techne, Cambridge, UK) and did not
contain live bacteria when assessed in cell cultures.
2.4. Assay for Sphingomyelinase Activity. Two different assays
of SMase activity in EB were employed. Accordingly, we
first used a fluorescent sphingomyelin analog, Bdp-SM, as
a substrate and monitored the appearance of the corre-
sponding fluorescent ceramide by analysis of the reaction
by TLC. EB (20–30 𝜇L, 109 IFU/mL) in SPG was added
to 50 𝜇M Bdp-SM in 0.5mM Hepes, 1.8mM MgCl
2
, 9mM
CaCl
2
, pH 7.4, or, when indicated, in the SPG buffer in
a total volume 0.25mL with the given ion concentrations.
After approximately 48 hrs at 37∘C with continuous stirring
1.75mL of chloroform/water/methanol (33 : 25 : 1, by vol.) was
added. The lower chloroform phase was collected and dried
under nitrogen. The residue was subsequently dissolved in
40 𝜇L of chloroform and a 20 𝜇L aliquot was applied onto
silicic acid coated plates. These were developed with 1,2-
dichloroethane/methanol/water (90 : 20 : 0.5, by vol.) and the
lipid spots visualized by UV illumination. Bdp-SM and Bdp-
cer were used as standards.
SMase activity in EB was measured also by the semi-
quantitative Amplex Red assay (Molecular Probes, Eugene,
OR), following the manufacturer’s instructions. This indirect
method is based on coupled enzymatic reactions. More
specifically, the phosphocholine moiety released by SMase
from sphingomyelin is first converted into choline by alkaline
phosphatase and further oxidized by choline oxidase to
betaine and H
2
O
2
. The latter then reacts with 10-acetyl-
3,7-dihydroxyphenoxazine (Amplex Red) in a reaction cat-
alyzed by horseradish peroxidase, generating the fluores-
cent resorufin, which is detected. The reaction mixture
[26] contained in the SPG-buffer and in a total volume of
0.2mL of 5mM10-acetyl-3,7-dihydroxyphenoxazine, 2.5mM
sphingomyelin, and 2% Triton X-100 (v/v), together with
the required cascade of the above enzymes. Reactions were
started at 37∘C by the addition of C. pneumoniae EB (from
0.5 × 107 to 3 × 107 IFUs, as indicated). SMase from S.
aureus (0.5mM) and 10 𝜇M H
2
O
2
were used as controls.
Fluorescence intensities weremeasured with SPECTRAFluor
Plus reader (Tecan AG, Hombrechtikon, Switzerland) using
excitation and emission wavelengths of 535 and 590 nm,
respectively. Based on comparison with S. aureus SMase we
could estimate the activity of this enzyme in EB in mU per
IFU.
2.5. Assay for the C. pneumoniae Internalization. To mon-
itor the attachment and internalization of C. pneumoniae,
confluent HL cell monolayers growing on glass coverslips in
24-well plates were incubated for 30min at 37∘C in serum-
free DMEM, further supplemented, when indicated, with
20 or 50mU/mL of Staphylococcus aureus SMase. The cells
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were then extensively washed with DMEM and inoculated
immediately with either C. pneumoniae K6 or metabolically
labelled C. pneumoniae K6 at a multiplicity of infection
(MOI) of 0.003–0.1. The cells were centrifuged at 2100 rpm at
room temperature and then incubated in serum-free DMEM
at 37∘C for 1 h, followed by washing with serum-free DMEM.
To remove attached but not internalized bacteria, the cells
were subjected to a mild treatment with trypsin [40] and
washed with serum-free DMEM.The cells suspended in PBS
were mixed with scintillation cocktail (Optiphase HighSafe3,
Wallac, Perkin Elmer life sciences, Turku, Finland) and the
radioactivity quantitated by a liquid scintillation counter
(1450-Microbeta, Wallac, Turku, Finland). To monitor the
growth of internalizedC. pneumoniae, the inoculated cultures
were further incubated for 48 h at 37∘C in complete DMEM
containing 0.5 𝜇g/mL cycloheximide after the monolayers
were fixed with methanol and the chlamydial inclusions were
stained with fluorescein-labeled anti-Chlamydia antibody
(Biorad, Hercules, CA). The inclusions were counted in 20
random 40x fields per coverslip. Data from three parallel
wells were combined to calculate the mean and standard
deviations.
2.6. Cloning of CPn0300 and C. muridarum TC 512.
Genomic DNA was prepared from C. pneumoniae using
MagNA Pure Compact nucleic acid isolation kit (Roche
Applied Science). The CPn0300 was amplified by PCR and
cloned into the BamHI-XhoI site of pGEX-4T-3 vector (GE
Healthcare Life Sciences, Uppsala Sweden). Sequencing the
cloned plasmid DNA using pGEX-specific primers verified
that the insert was CPn0300. The recombinant plasmid was
transformed into E. coli JM109 and BL-21.The corresponding
gene from C. muridarum (TC 512) was amplified by PCR
and cloned into the SalI-NotI site of the pGEX-4T-3 vector.
The expression of CPn0300 and TC 512 was induced with
0.5mM IPTG. The E. coli cells were harvested at 3 hours
postinduction by centrifugation (1500 g, 15 minutes) and
washed with 10mM Tris-HCl (pH 8.0) containing 0.1M
NaCl and 1mM EDTA. Cells were suspended in 25mM
Tris-HCl (pH 8.0) containing 50mM glucose and 10mM
EDTA. Egg lysozyme was added to the suspension (final
concentration 100𝜇g/mL) and the mixture was incubated
for 10 minutes. 10mM Hepes-NaOH (pH 7.5) containing
0.25M sucrose, 1mM EDTA, and protease inhibitor cocktail
was added to cell suspension and the resulting mixture was
sonicated five times with a probe-type sonicator at 20W for
10 minutes. The cell lysates were analyzed for SMase activity
by using Amplex Red assay. To assess the production of
recombinant proteins, the induced cell lysates were analyzed
by SDS-PAGE.
3. Results
Amplex Red assay was used to confirm SMase activity in C.
pneumoniae and for a rough quantitation of this enzymatic
activity (Figures 4(a), 4(b), and 4(c)). In this method, the
phosphocholine headgroup released by SMase is converted
in a cascade of coupled enzymatic reactions to a fluorescent
end product thus allowing monitoring of the progress of the
hydrolytic reaction by the increment in fluorescence with
time. Based on the activity of S. aureus SMase as an internal
standard we could estimate SMase activity to be roughly
0.3 pU per IFU. The measured activity was proportional to
the amount of bacteria added (Figure 4(a)). The presence
of 9mM Ca2+ enhanced the activity (Figure 4(b)), whereas
2mM Mg2+ was slightly inhibitory (Figure 4(c)). Reduced
activity was measured for EB maintained for 5min at 60∘C
or 90∘C (Figure 7).
We then investigated if prior hydrolysis of the host
cell plasma membrane sphingomyelin by exogenously added
SMase would affect the infection of the cells by C. pneumo-
niae. Interestingly, preincubation of HL cells with S. aureus
SMase prior to their inoculation with EB attenuated the
bacterial entry and/or growth.This effect was proportional to
the amount of SMase added (Figure 5(a)). As this attenuation
could also result from an apoptotic challenge of the cells due
to SMase we checked if the pretreatment of cells with SMase
caused activation of caspase-3. However, no increase in the
activity of this enzyme was evident (data not shown). This
result proves that the apoptotic challenge of formed ceramide
cannot be the reason for attenuation. Interestingly, we could
not see the attenuation if HL cells were infected with mouse
Chlamydia, Chlamydia muridarum (data not shown). The
above was confirmed in experiments where radioactive EB
were used to quantify the internalization by cultured cells,
with heparin preventing the binding of EB to the host cell
([41], Figure 5(b)). Our data thus suggest that the availability
of sphingomyelin on the external surface of host cells could
represent a limiting factor for C. pneumoniae internalization.
Putative C. pneumoniae outer surface proteins [34] were
aligned by T-coffee with a reference group of sphingomyelin-
ases fromdiverse species and subfamilies ranging from bacte-
rial enzymes to human neutral sphingomyelinases (Table 1).
Only the entire sequences of these proteins were included. T-
coffee scores sequence alignments in a range of 1–100, with
the range 70 to 100 regarded as good while values below
50 are poor, revealing a lack of similarity. Interestingly,
the C. pneumoniae protein Tr|Q9Z8N8|Q9Z8N (CPn0300,
an omp85 analog) scored 73. In the alignment of the
active site containing domains of the three neutral SMases
highest sequence similarity of CPn0300 was evident with
the human neutral SMase sp|O60906|NSMA (Figure 1).
Of particular interest are the similarities in the sequences
known to be involved in proton binding [42] and substrate
recognition [43] by the NSMase protein family, the highly
conserved histidine-proline loop [42] being found in the
latter domain (Figure 2). Against the selected NSMase
protein subfamily CPn0300 scored 40, which was roughly
the same as the similarity of the NSMase of baker’s yeast
(sp|P40015|ISC1 YEAST) to the selected NSMase protein
subfamily. Two human enzymes, NSMase1 and NSMase2,
have been identified, with the former representing a
distant homolog of bacterial SMases [44]. Comparison
of these two SMases with CPn0300 of C. pneumoniae
suggests the latter to belong to the group 1 enzymes
(Figure 1). Interestingly, Pfam is a large collection of
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sp|O60906 |NSMA
sp|O60906 |NSMA
sp|O60906 |NSMA
sp|O60906 |NSMA
sp|O60906 |NSMA
sp|O60906 |NSMA
sp|O60906 |NSMA
sp|O60906 |NSMA
sp|O60906 |NSMA
sp|O60906 |NSMA
sp|O60906 |NSMA
sp|O60906 |NSMA
sp|O60906 |NSMA
sp|O60906 |NSMA
sp|O60906 |NSMA
--------------IYLAHRVAQAWELAQFIHHTSKKADVVLLCG
AGLYHPDIVEQDSLAITNYLHNNGYADAIVNSHYDLDDKGNILLY
sp|O60906 |NSMA
sp|O60906 |NSMA
IKINEGPCGKIKQLTFSGISRSEKSDIQEFIQTKQHSTTTSWFTG
M---KLNFSLRLRIFNLNCWGIPYLSKHRADRMRRLGDFLN----
Cons
------------QESFDLALLEEVWSEQDFQYLRQKLSPTYPAAH
-FSEGKTNIALHLIAKPSIRNIHISGNQVVPEHKILKTLQIYRND
HFRSGIIGSGLCVFSKHPIQELT----------QHIYTLNGYPYM
LFEREKFLKGLDDLRTYYLKRGYFASSVDY-SLEHNQEKGHIDVL
IHHGDWFSGKAVGLLVLHLSGMVLNAYVTHLHAEYNRQKD-----
DLNMHP---------------------------------------
MDIDRGSRYTLGHVHIQGFEVLPKRLIEKQSQVGPNDLYCPD-KI
-----------------------------------EDLGCCLLKE
WDGAH-------------KIKQTYAKYGYINTNVDVLFIPHATRP
WTGLHDAYLETRDFKGSEEGNTMVPKNCYVSQQ------------
: : : :
IYDVTYEVSEGSPYKVGLIKITGNTHTKSDVILHETSLFPGDTFN
---------ELKPFPFGV---------RIDYVLYKAV--------
. .
. . . .
. .
:
: : : : : :
: : : : : :
RLKLEDTEQRLRNTGYFQSVSVYTVRSQLDPMGNADQYRDIFVEV
-------------SGFYISCKSFETTTGFDP--------------
KETTTGNLGLFLGFSSLDNLFGGIELSESNF---DLFGARNIFSK
--------------------HSGTPLSDHEALMATLFVRHSPPQQ
: ::
GFRCLRGGGEHLFLKANFGDKVTDYTLKWTKPHFLNT--PWILGI
. . : . : . : : : : : . : : . : : : :
GL------LLLALLCVLAAGGGAGEAAILLW--------------
. : . . . :
LHEKRKFLLGPNIDSNKGFVSAAGVNLNYDSVDSPRTPTTGIRGG
------------------------------------TPSVGL---
: .
.
:
VTFEVSGLGGTYHFTKLSLNSSIYRKLTRKGILKIKGEAQFIKPY
----VLWAGAFYLFHVQEVNGLYRAQAELQHVLGRAREAQDLGP-
. . : . : : : :
Bad Avg Good
tr|Q9Z8N8|Q9Z8N MLIMRNKVILQISILALIQTPLTLFSTEKVKEGHVVVDSITIITE
Cons
tr|Q9Z8N8|Q9Z8N
Cons
tr|Q9Z8N8|Q9Z8N
Cons
tr|Q9Z8N8|Q9Z8N
Cons
tr|Q9Z8N8|Q9Z8N
Cons
tr|Q9Z8N8|Q9Z8N
Cons
tr|Q9Z8N8|Q9Z8N
Cons
tr|Q9Z8N8|Q9Z8N
Cons
tr|Q9Z8N8|Q9Z8N
Cons
tr|Q9Z8N8|Q9Z8N
Cons
tr|Q9Z8N8|Q9Z8N
Cons
tr|Q9Z8N8|Q9Z8N
Cons
tr|Q9Z8N8|Q9Z8N
Cons
tr|Q9Z8N8|Q9Z8N
Cons
tr|Q9Z8N8|Q9Z8N
Cons
tr|Q9Z8N8|Q9Z8N
Cons
tr|Q9Z8N8|Q9Z8N
∗
∗
∗ ∗
∗
∗∗
∗∗ ∗
∗
∗
∗ ∗∗ ∗∗
∗
∗
∗
∗
∗ ∗ ∗ ∗ ∗ ∗ ∗∗∗ ∗
∗ ∗
∗ ∗∗ ∗∗∗
∗ ∗ ∗ ∗ ∗ ∗
∗ ∗∗
∗ ∗ ∗∗
∗ ∗ ∗ ∗
∗
∗∗ ∗
∗ ∗ ∗ ∗ ∗ ∗
∗ ∗ ∗ ∗∗ ∗
∗ ∗ ∗ ∗
∗∗ ∗ ∗∗:
: :
: :
:
:
: : : : : : : ::
: : : : : : :
: : : : : : : : :
: : : : : : : : :
: : : : : : : : : :.
. .
.
. . .
.
. .
. . . .
. . .
. ..
. . . . .
. . . . . ..
GENASNKHPLPKLKTRSGALFSQLDFDEDLRILAKEYDSVEPKVE
NPSSTHGPAERSPLMCVLKEAWTELGLGMAQARWWATFASYVIGL
ELDKSINRALSKDYAVQTYGGNVSTTYILNEHLKYGLFYRGSQTS
SNTTAEGVPVSERFFLGGETTVRGYKSFIIGPKYSATEPQGGLSS
-------------------------------------EPQPAL--
LLISEEFQYPLIRQPNISAFVFLDSGFVGLQEYKISLKDLRSSAG
--------------------------LLGQQEGDRTKEQ------
: : . : : :
∗
∗ ∗∗
∗∗ ∗
Figure 1: T-coffee alignment of the sequences of tr|Q9Z8N8|Q9Z8N of Chlamydia pneumoniae (CPn0300) and human neutral
sphingomyelinase, NSMase sp|O60906|NSMA. Putative proton binding site and proton acceptor site are underlined (residues 220 to 229
and 463 to 465 in CPn0300, resp.).
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Bad Avg Good
: 59
: 85
: 86
: 85
LTFSGISRSEKSDIQEFIQTKQHSTTTSWFTGAGLYH
PDIVEQD
L-------------
AQFIHHTSKNADVVLLCGDLNMHPKDLGC-
L-------------
AQFIHHTSKKANVVLLCGDLNMHPKDLGC-
L-------------
AQFIHHTSKKADVVLLCGDLNMHPEDLGC-
Cons : : : : : :. . . . .
tr|Q9Z8N8|Q9Z8N
tr|Q9Z8N8|Q9Z8N
sp|O70572|NSMA
sp|O70572|NSMA
sp|Q9ET64|NSMA
sp|Q9ET64|NSMA
sp|O60906 |NSMA
sp|O60906 |NSMA
∗ ∗∗ ∗ ∗∗
Figure 2: T-coffee alignment of CPn0300 (top) with the sequences
involved in proton binding and substrate recognition by type 1 neu-
tral SMases sp|O70572|NSMA (Mus musculus), sp|Q9ET64|NSMA
(Rattus norvegicus), and sp|O60906|NSMA (Homo sapiens) as
indicated.
multiple sequence alignments and hidden Markov models
covering many common protein domains and families.
The Pfam motif of IMP dehydrogenase/GMP reductase
(http://myhits.isb-sib.ch/cgi-bin/motif scan) in CPn0300
was found beginning of amino acid 67 to 388 [36].
Following the tentative identification of CPn0300 as a
potential SMase it was of interest to study if isolated C.
pneumoniae EB possess this enzymatic activity. This was
first assessed by incubating purified EB with sphingomyelin
bearing the covalently linked Bodipy fluorophore in the N-
acyl chain. After 48 hrs of incubation at 37∘C the lipids
were isolated on TLC and visualized by UV-illumination
(Figure 3). Formation of ceramide was evident in the pres-
ence of C. pneumoniae EB and its content did depend on the
amount of bacteria added, as shown by visual inspection of
the lanes for the amount of ceramide formed in the presence
of approximately 33 × 106 and 66 × 106 IFUs (Figure 3, lanes
B and C, resp.).
The importance of host cell surface sphingomyelin to
the internalization process of C. pneumoniae was studied.
Pretreatment of host cells with exogenously added SMase
decreased the formation of chlamydial inclusions in the
C. pneumoniae infection. This phenomenon correlated with
the amount of SMase added. With 50mU/mL SMase, the
formation of inclusions was inhibited by more than 50%.
Pretreatment of the host cells by SMase consumed the SM
available on the plasmamembrane ofHL cells thus decreasing
chlamydial intake. Earlier, Allan and Quinn [45] showed that
after SMase hydrolysis on the surface of BHK cells, it took
3 hours to get SM content back to normal on the plasma
membrane. They also showed that the SM of an inaccessible
pool (inside the cell) will not equilibrate with the plasma
A B C D
Figure 3: TLC analysis on silicic acid coated plates of the hydrolysis
of the fluorescent Bdp-sphingomyelin (lane A) to Bdp-ceramide
(lane D). Formation of fluorescent ceramide from Bdp-SM (50 𝜇M
final concentration) in 0.5mM Hepes, 1.8mM MgCl
2
, and 9mM
CaCl
2
; pH 7.4wasmonitored after the addition of 3.3× 107 (inclusion
forming units (IFUs) (lane B) and 6.6 × 107 IFUs of intact C.
pneumoniae (lane C) in the same buffer. Incubation for 48 hrs at
37∘C was used to ensure sufficient product formation so as to
allow the detection of ceramide upon TLC despite losing some of
this lipid in extraction. The TLC plates were developed with 1,2-
dichloroethane/methanol/water (90 : 20 : 0.5, by vol) and the lipids
localized by illumination with a UV lamp.
membrane pool, even after prolonged incubation. Instead,
Triton X-100 treatment of the cells caused an almost complete
breakdown of total BHK sphingomyelin.
Because sphingomyelinase activity in C. pneumoniae
has not been previously reported, the membrane proteins
potentially responsible for the SMase activity were further
investigated.
To construct a recombinant plasmid for expression of
a C. pneumoniae sphingomyelinase coding sequence, C.
pneumoniae DNA was amplified using CPn0300 specific
primers. After PCR, the size of the PCR product was verified
by agarose gel electrophoresis. A product of 2387 bp was
detected, as expected. The PCR product was digested with
BamHI and XhoI and ligated to a pGEX-4T-3 vector and the
recombinant plasmid was transformed into E. coli. Plasmid
DNA was purified from the transformed E. coli and digested
with BamHI, XhoI, and PstI. The restriction enzyme analysis
suggested that the insert was CPn0300.This was further con-
firmed by sequencing the plasmid DNA using pGEX-specific
primers. Finally, induced cell lysates expressing CPn0300 that
ran on the SDS-page showed production of a glutathione-s-
transferase (GST)-CPn0300 fusion protein of approximately
110–115 kDs in size. E. coli transformed with parental pGEX-
4T-3 was used as a control for GST expression (Figures 6(a)
and 6(b)).
Sphingomyelinase activity present in the cell lysates was
measured using Amplex Red assay. The activity was signif-
icantly higher in the lysates of E. coli expressing CPn0300
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Figure 4: (a) Time courses for the increase in resorufin fluorescence FI a.u. (fluorescence intensity, arbitrary units) due to C. pneumoniae is
measured by the Amplex Red assay. The reactions were started by the addition of 0.5 × 107 (◼), 1 × 107 (e), and 3 × 107 (󳵳) inclusion forming
units (IFUs) of bacteria in SPG and in a total volume of 200𝜇L at 37∘C. (b) SMase activity of C. pneumoniae measured by the Amplex Red
assay. The reactions were started by the addition of 3 × 107 IFUs (in 30𝜇L of SPG buffer) in the presence of either 9mM CaCl
2
(◼) or 9mM
CaCl
2
and 35mM EDTA (e) and in a total volume of 200𝜇L. Temperature was 37∘C. (c) SMase activity of C. pneumoniae in SPG buffer (󳵳)
and with either 2mMMgCl
2
(◼) or 2mMMgCl
2
and 4mM EDTA (e). The Amplex Red assays for SMase were started by the addition of 1.5
× 107 IFUs of bacteria, incubated in a total volume of 200𝜇L at 37∘C.
than in cells having the plain vector or in lysates expressing
C. muridarum TC 512 (Figures 6(a) and 6(b)). This data is
in consistence with the fact that we could not see inhibitory
effect of SMase pretreatment on the formation of inclusion
bodies in HL cells when HL cells were infected with C.
muridarum.
4. Discussion
The genus Chlamydia includes several speciesof small intra-
cellularly growing bacteria, which can enter andmultiply in a
variety of human cells [46], including both professional and
nonprofessional phagocytes, and cause a variety of diseases
in both human and animal hosts [47]. C. trachomatis causes
sexually transmitted infections and blinding trachoma, while
C. psittaci is a pathogen primarily for birds and mammals,
being only occasionally transmitted to humans. C. pneu-
moniae is a common human pathogen causing respiratory
tract infections associated with chronic conditions such as
atherosclerosis and coronary heart disease [48, 49], asthma
[50], chronic bronchitis [51], reactive arthritis [52], and
Alzheimer’s disease [53].
The viability of Chlamydia and its surface structure are
important to the attachment and entry of thismicrobe into its
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Figure 5: Impact of a pretreatment of the host cells by exogenous SMase on the entry and growth of C. pneumoniae. (a) HL cells were
incubated for 30min at 37∘Cwith either 20 or 50mU/mL of S. aureus SMase, as indicated, either before (black bars) or after (white bars) their
inoculation with C. pneumoniae (0.1 × 106 IFUs). Growth of C. pneumoniae was detected at 48 hours postinoculation. (b) Internalization of
C. pneumoniae by HL cells pretreated with SMase (20 or 50mU/mL, final concentration), followed by inoculation with metabolically labelled
bacteria. Radioactivity in cells was measured after inoculation and trypsin treatment. Heparin (500 𝜇g/mL) inhibits attachment of bacteria
to the host cells and was employed as a negative control.The error bars indicate standard deviations from triplicate wells. Student’s t-test gave
values of ∗∗𝑃 < 0.01 and ∗∗∗𝑃 < 0.001 for the difference between the cells treated with SMase and controls in DMEM.
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Figure 6: Measurement of SMase activity from lysates of JM109 transformed with recombinant pGEX-4T-3 by Amplex Red assay. Resorufin
fluorescence FI a.u. (fluorescence intensity, arbitrary units) was measured. E. coli JM109 transformed with recombinant pGEX-4T-3 were
induced with 0.5mM IPTG. Three hours later, the cells were lysed as described in Section 2. Ten 10 𝜇L of the lysate was used in the
measurement done after 30 minutes of incubation at 37∘C. (a) SMase activity of free different clones of CPn0300 was measured. (b) SMase
activity of E. coli lysates expressing CPn0300 and C. muridarum TC 512 was measured. Controls express plain vector.
host cells.The binding ofC. trachomatis to host cells increases
with temperature between 0 and 37∘C [54]. While UV-
inactivatedChlamydiaEB remain capable of entry intomouse
fibroblasts [55], heat treatment (i.e., 5min at 60 or 90∘C) of EB
reduces their uptake [54]. Our current study demonstrates
SMase activity in UV inactivated EB (data not shown) and
decreased activity in heat treated EB (Figure 7). As far as
we are aware this is the first report on an enzymatic activity
in chlamydial EB. The substrate for SMase, sphingomyelin,
is an abundant phospholipid in eukaryote membranes and
it is enriched in the outer leaflet of the plasma membrane
[56] thus being readily accessible to invading microbes.
The observed transient externalization of phosphatidylserine
accompanying the entry of C. pneumoniae into epithelial,
endothelial, granulocytic, and monocytic cells [57] could
reflect an accumulation of ceramide in the host cell mem-
branes upon their contact with EB. Interestingly, the exposure
of PS on the outer cell surface of host cells has been reported
upon infection byP. falciparum [58] and SMase activity of this
parasite has been concluded to be essential for the infection
of erythrocytes [7]. In addition to its role in apoptosis [59],
ceramide has been shown to be intimately involved also in
the signaling cascades underlying inflammation [1, 2, 4, 5].
Precursor of ceramide, sphingomyelin, has a putative role in
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Figure 7: Effect of heat treatment on the SMase activity of C.
pneumoniae. Bacteria were incubated for 5min at either 60 (◼) or
90∘C (e), and bacteria maintained at 37∘C were used as a control
(󳵳). Amplex Red assays were started by adding 1 × 107 IFUs of
bacteria and incubated in a total volume of 200 𝜇L at 37∘C. Resorufin
fluorescence FI a.u. (fluorescence intensity, arbitrary units) was
measured.
inclusion body formation and intracellular trafficking [60].
It seems feasible that by increasing the cellular levels of
ceramide in the affected host tissues the presence of C.
pneumoniae could perturb the metabolic state of cells and
tissues and thus contribute to the pathophysiology of the
secondary disorders connected to Chlamydia infection.
In general, the sequence similarity between different
SMases such as those in our reference group (Table 1) is
weak, in spite of the fact that these proteins possess the
same catalytic activity. Because of this high variability of
the SMase sequences their identity goes easily unnoticed
when stringent similarity searches are used. Nevertheless,
the assessment of CPn0300 with Nomad (Neighborhood
Optimization for Multiple Alignment Discovery, see Expasy,
http://ca.expasy.org/) reveals an equal degree of sequence
similarity to the endonuclease/exonuclease/phosphatase do-
main of SMases as between most nonmammalian SMases.
Total alignment with N-SMase gave best overall results.
Interestingly, also the pfam ls:IMPDH (IMP dehydroge-
nase/GMP reductase domain) motif is present in CPn0300,
between residues 67 and 388. This domain belongs to
the common phosphate binding site in the TIM bar-
rel superfamily and includes various phosphatases and
lipases [61]. CPn0300 thus appears to possess the same
active domain site as alkaline sphingomyelin phosphodi-
esterases. The catalytic domain of human neutral SMases
belongs to the endonuclease/exonuclease/phosphatase fam-
ily (http://www.uniprot.org/uniprot/O60906). Our sequence
analysis of C. pneumoniae suggests the omp85 homolog
CPn0300 to be a possible candidate responsible for the SMase
activity measured for this microbe. Along these lines it seems
possible that SMase activity could be found in other bacterial
outer membrane proteins, the omp85 family in particular.
However, it is as well possible that some of the SMases
are not intrinsic SMase of C. pneumonia but carried on
the top of the capsid from the host cell. Whichever the
case, our data also provide support to the view that this
enzymatic activity is involved in the host cell membrane
manipulation of C. pneumoniae that is important in the
host cell internalisation and externalisation. In keeping with
this notion, omp85 specific antibodies have been shown to
inhibit chlamydial infectivity in vitro [62].While the function
of CPn0300 [34] has remained elusive, this putative outer
surface protein is highly conserved between the different C.
pneumoniae strains [63]. The proteins in the omp85 family
have been shown to have various membrane affecting roles.
In E. coli YaeT (an ortholog of omp85) has a critical role in
the outermembrane assembly [64]. PorB, a component of the
chlamydial outer membrane, has pore forming activity [65];
however, this activity was not detected for chlamydial omp85
when incorporated into liposomes [62].
Enzymatic manipulation of membrane lipids can be used
for a number of different purposes [22]. Along these lines
the most common human pathogen S. aureus secretes SMase
[66], which is lytic to the host cells thus allowing the microbe
to use the host tissues for nutrition. In contrast, the life cycle
of Chlamydia requires the host cell to remain viable, so as
to allow the EB→RB conversion and subsequent replication
within the host. Accordingly, only a relative low SMase
activity is adequate to avoid triggering of apoptosis in the
host too early, before completion of the replication of the
invading Chlamydia. Accordingly, it seems feasible that EB-
catalyzed formation of ceramide could trigger the death of
the host after the completion of the replication cycle. Finally,
it is possible that different mechanisms of entry are utilized
by different Chlamydiae as well as in the entry into different
cell types. Understanding these processes would shed light
on pathogenesis of chlamydial infections and potentially
facilitate the development of novel means for therapeutic
intervention.
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